Michela Bianchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michela Bianchi has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Alessio Polymeropoulos
Biostatistics for Clinical Research, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
2 shared publications- Andreina Oliverio
Nutrition Research and Metabolomics, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
2 shared publications - Francesco Segrado
Nutrition Research and Metabolomics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy
2 shared publications Patrizia Pasanisi
Nutrition Research and Metabolomics, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
2 shared publicationsRoberto Agresti
Senologia Chirurgica Integrata, Dipartimento di Chirurgia Oncologica, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
2 shared publicationsRosalba Miceli
Biostatistics for Clinical Research, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
2 shared publications
Latest Publications
- Open Access
- 24 June 2026
- Published by SAGE Publications in The International Journal of Biological Markers
- Vol. 41
Luminex assay of plasma IL-6, TNF-α, leptin, and adiponectin: Impact of anticoagulants, single-well analysis, and freeze–thaw stability
Background: Chronic inflammation from visceral obesity contributes to metabolic disorders and cancer through cytokine imbalance. Accurate cytokine measurement is crucial to understand these links. This study examined challenges in quantifying interleudin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), leptin, and adiponectin in historical biobank samples with limited volumes and varying plasma anticoagulants. Methods: Luminex-MAGPIX platform was used to evaluate three analytical aspects. Single-well precision was assessed via intra- and inter-assay coefficients of variability (CVs). Plasma matrix effects were examined by pairwise comparison of analyte concentrations across citrate, heparin, and EDTA plasma from 10 volunteers. Cytokine stability was tested after one freeze-thaw cycle (analysis of variance). Results: Single-well measurements showed good precision (CV <10% intra-assay, <15% inter-assay). Plasma matrix affected absolute concentrations. In particular, all analytes were lower in citrate than in EDTA and heparin, but relative relationships and subject-specific rankings remained preserved. Pearson correlation coefficients for IL-6, leptin, and adiponectin were high across matrices (r-range = 0.952–0.999), whereas correlations for TNF-α were lower (r-range = 0.897–0.972). Freeze–thaw stability was analyte- and matrix-dependent: leptin remained stable in heparin and EDTA but decreased 9.5% in citrate; adiponectin was stable in citrate but decreased in heparin (−9.0%) and EDTA (−11.8%). IL-6 and TNF-α were unaffected. Conclusion: IL-6, TNF-α, leptin, and adiponectin were accurately quantified using single-well Luminex assays and showed reasonable tolerance to a single freeze–thaw cycle, offering a practical strategy for preserving valuable specimens. Although plasma anticoagulant affected absolute concentrations, the preservation of relative analyte rankings permits their use in most study designs but limit absolute value comparisons.
- 24 June 2026
- Published by SAGE Publications in The International Journal of Biological Markers
- Vol. 41
Open AccessLuminex assay of plasma IL-6, TNF-α, leptin, and adiponectin: Impact of anticoagulants, single-well analysis, and freeze–thaw stability
Background: Chronic inflammation from visceral obesity contributes to metabolic disorders and cancer through cytokine imbalance. Accurate cytokine measurement is crucial to understand these links. This study examined challenges in quantifying interleudin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), leptin, and adiponectin in historical biobank samples with limited volumes and varying plasma anticoagulants. Methods: Luminex-MAGPIX platform was used to evaluate three analytical aspects. Single-well precision was assessed via intra- and inter-assay coefficients of variability (CVs). Plasma matrix effects were examined by pairwise comparison of analyte concentrations across citrate, heparin, and EDTA plasma from 10 volunteers. Cytokine stability was tested after one freeze-thaw cycle (analysis of variance). Results: Single-well measurements showed good precision (CV <10% intra-assay, <15% inter-assay). Plasma matrix affected absolute concentrations. In particular, all analytes were lower in citrate than in EDTA and heparin, but relative relationships and subject-specific rankings remained preserved. Pearson correlation coefficients for IL-6, leptin, and adiponectin were high across matrices (r-range = 0.952–0.999), whereas correlations for TNF-α were lower (r-range = 0.897–0.972). Freeze–thaw stability was analyte- and matrix-dependent: leptin remained stable in heparin and EDTA but decreased 9.5% in citrate; adiponectin was stable in citrate but decreased in heparin (−9.0%) and EDTA (−11.8%). IL-6 and TNF-α were unaffected. Conclusion: IL-6, TNF-α, leptin, and adiponectin were accurately quantified using single-well Luminex assays and showed reasonable tolerance to a single freeze–thaw cycle, offering a practical strategy for preserving valuable specimens. Although plasma anticoagulant affected absolute concentrations, the preservation of relative analyte rankings permits their use in most study designs but limit absolute value comparisons.
- Open Access
- 27 April 2026
- Published by SAGE Publications in Tumori Journal
- Vol. 112 (4) , 355-365
Breath analysis for non-invasive detection of breast cancer: A prospective observational cohort study
Purpose and design: BreathBC is a multicenter prospective observational cohort study aimed at comparing metabolic profiles from exhaled breath of patients with breast cancer (BC) and malignancy-free controls. The study accounts for the novelty and complexity of breath analysis, with a particular emphasis on the standardization of each step in the process. Participants: Women with primary BC without distant metastasis, women carriers of germline BRCA1/2 pathogenic variants and controls were consecutively recruited in two clinical independent cohorts and two technical validation cohorts. Breath samples were collected and linked to clinical breast status, personal, medical and lifestyle data that were retrieved using a questionnaire focused on factors potentially affecting breath analysis. Results: Among 1010 participants, a group of 846 subjects, compliant with criteria of recruitment and sampling of the study, were preliminarily characterized. The mean age was 61 years for patients with BC and 58 years for controls, with 71% of women in post-menopause. The control group included 48% of participants with benign disease. Hypertension was the main age-related morbidity observed in 28% of participants and 10% were smokers. Among patients with BC, 15% had in situ disease and 85% an invasive cancer whose sub-typing presented a high prevalence of luminal subtypes, in agreement with the consecutive recruitment. Future activities will be focused on data analysis of breathomics data and on technical enhancement of prototypes used for sampling and instrumental analysis.
- 27 April 2026
- Published by SAGE Publications in Tumori Journal
- Vol. 112 (4) , 355-365
Open AccessBreath analysis for non-invasive detection of breast cancer: A prospective observational cohort study
Purpose and design: BreathBC is a multicenter prospective observational cohort study aimed at comparing metabolic profiles from exhaled breath of patients with breast cancer (BC) and malignancy-free controls. The study accounts for the novelty and complexity of breath analysis, with a particular emphasis on the standardization of each step in the process. Participants: Women with primary BC without distant metastasis, women carriers of germline BRCA1/2 pathogenic variants and controls were consecutively recruited in two clinical independent cohorts and two technical validation cohorts. Breath samples were collected and linked to clinical breast status, personal, medical and lifestyle data that were retrieved using a questionnaire focused on factors potentially affecting breath analysis. Results: Among 1010 participants, a group of 846 subjects, compliant with criteria of recruitment and sampling of the study, were preliminarily characterized. The mean age was 61 years for patients with BC and 58 years for controls, with 71% of women in post-menopause. The control group included 48% of participants with benign disease. Hypertension was the main age-related morbidity observed in 28% of participants and 10% were smokers. Among patients with BC, 15% had in situ disease and 85% an invasive cancer whose sub-typing presented a high prevalence of luminal subtypes, in agreement with the consecutive recruitment. Future activities will be focused on data analysis of breathomics data and on technical enhancement of prototypes used for sampling and instrumental analysis.
- Open Access
- 29 September 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (19) , e71279
Explorative Detection of Fractional Exhaled Nitric Oxide ( FeNO ) in Exhaled Breath of Patients With Breast Cancer
Background: Nitric oxide (NO), a gaseous messenger with pleiotropic functions, plays a role in cancer, including breast cancer (BC). Considering the high permeability and leakiness of NO across tissues and the increased levels of NO recently reported in exhaled breath and blood of patients with lung cancer, we explored exhaled NO levels in patients with BC in a future perspective of non‐invasive cancer detection. Patients and Methods: Fractional exhaled NO (FeNO) levels were detected in the breath of 192 women with BC and malignancy‐free controls employing a widely used point‐of‐care (POC)‐based system previously developed for asthma monitoring. Results: FeNO levels were lower in BC patients compared to controls, with the lowest levels in women with HER2‐expressing tumors. In univariate and multivariate analyses and after adjustment for age, smoking, and asthma, this difference was not significant. The effects of smoking were not statistically significant, whereas asthmatic subjects had significantly higher levels of FeNO ( p = 0.006). Neither menopause nor BMI had a significant impact on FeNO levels. Conclusion: Our explorative work indicates that FeNO levels are heterogeneously detected in the breath of BC patients in the absence of confounding effects and are associated with the clinical characteristics of the disease. More sensitive detection of exhaled NO and larger cohorts enriched with ER negative BC are needed to further explore the potential of NO in non‐invasive detection of BC, either alone or in conjunction with other BC‐related volatile markers, and extending the NO measurement to blood or tissues.
- 29 September 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (19) , e71279
Open AccessExplorative Detection of Fractional Exhaled Nitric Oxide ( FeNO ) in Exhaled Breath of Patients With Breast Cancer
Background: Nitric oxide (NO), a gaseous messenger with pleiotropic functions, plays a role in cancer, including breast cancer (BC). Considering the high permeability and leakiness of NO across tissues and the increased levels of NO recently reported in exhaled breath and blood of patients with lung cancer, we explored exhaled NO levels in patients with BC in a future perspective of non‐invasive cancer detection. Patients and Methods: Fractional exhaled NO (FeNO) levels were detected in the breath of 192 women with BC and malignancy‐free controls employing a widely used point‐of‐care (POC)‐based system previously developed for asthma monitoring. Results: FeNO levels were lower in BC patients compared to controls, with the lowest levels in women with HER2‐expressing tumors. In univariate and multivariate analyses and after adjustment for age, smoking, and asthma, this difference was not significant. The effects of smoking were not statistically significant, whereas asthmatic subjects had significantly higher levels of FeNO ( p = 0.006). Neither menopause nor BMI had a significant impact on FeNO levels. Conclusion: Our explorative work indicates that FeNO levels are heterogeneously detected in the breath of BC patients in the absence of confounding effects and are associated with the clinical characteristics of the disease. More sensitive detection of exhaled NO and larger cohorts enriched with ER negative BC are needed to further explore the potential of NO in non‐invasive detection of BC, either alone or in conjunction with other BC‐related volatile markers, and extending the NO measurement to blood or tissues.
- Open Access
- 9 August 2025
- Published by SAGE Publications in Tumori Journal
- Vol. 111 (5) , 390-399
The e-BRAVE study: A prospective web-based cohort and biobank of women carriers of BRCA mutations
Background: Women carriers of BRCA1/2 mutations face a very high lifetime risk (penetrance) of developing breast and/or ovarian cancer. A sizeable proportion of carriers, however, does not develop cancer at all or develop it only late in life, thus suggesting a potential modulation of this risk. Epidemiological studies have suggested that other genetic (polymorphisms) and environmental factors (lifestyle) affect penetrance. However, data regarding these associations mainly come from retrospective case-control analyses and the results are likely to be distorted by bias. Aims: The e-BRAVE (Brca, ReseArch, Virtual, Education) study aims to create a web-based prospective cohort and biological bank of unaffected women carriers of BRCA1/2 mutations to investigate the role of polymorphisms and environmental factors, and their interaction, in the occurrence of primary BRCA-related cancers. Methods: An innovative digital platform (including a mobile App) will be used to empower the synergy between participants and researchers, supporting engagement with women, adherence to intervention plan, self-empowerment, flanked by activities tracking and monitoring. Results: Based on the incidence data in previous studies, we estimate to observe an overall incidence of ~3.7% year. Conclusion: The success of this study will ensure the definition of further predictive risk models and comprehensive recommendations aimed at improving management and health of BRCA women.
- 9 August 2025
- Published by SAGE Publications in Tumori Journal
- Vol. 111 (5) , 390-399
Open AccessThe e-BRAVE study: A prospective web-based cohort and biobank of women carriers of BRCA mutations
Background: Women carriers of BRCA1/2 mutations face a very high lifetime risk (penetrance) of developing breast and/or ovarian cancer. A sizeable proportion of carriers, however, does not develop cancer at all or develop it only late in life, thus suggesting a potential modulation of this risk. Epidemiological studies have suggested that other genetic (polymorphisms) and environmental factors (lifestyle) affect penetrance. However, data regarding these associations mainly come from retrospective case-control analyses and the results are likely to be distorted by bias. Aims: The e-BRAVE (Brca, ReseArch, Virtual, Education) study aims to create a web-based prospective cohort and biological bank of unaffected women carriers of BRCA1/2 mutations to investigate the role of polymorphisms and environmental factors, and their interaction, in the occurrence of primary BRCA-related cancers. Methods: An innovative digital platform (including a mobile App) will be used to empower the synergy between participants and researchers, supporting engagement with women, adherence to intervention plan, self-empowerment, flanked by activities tracking and monitoring. Results: Based on the incidence data in previous studies, we estimate to observe an overall incidence of ~3.7% year. Conclusion: The success of this study will ensure the definition of further predictive risk models and comprehensive recommendations aimed at improving management and health of BRCA women.
- Open Access
- 6 December 2022
- Published by MDPI AG in Nanomaterials
- Vol. 12 (23) , 4330
Fe3O4-Halloysite Nanotube Composites as Sustainable Adsorbents: Efficiency in Ofloxacin Removal from Polluted Waters and Ecotoxicity
The present work aimed at decorating halloysite nanotubes (HNT) with magnetic Fe3O4 nanoparticles through different synthetic routes (co-precipitation, hydrothermal, and sol-gel) to test the efficiency of three magnetic composites (HNT/Fe3O4) to remove the antibiotic ofloxacin (OFL) from waters. The chemical–physical features of the obtained materials were characterized through the application of diverse techniques (XRPD, FT-IR spectroscopy, SEM, EDS, and TEM microscopy, thermogravimetric analysis, and magnetization measurements), while ecotoxicity was assessed through a standard test on the freshwater organism Daphnia magna. Independently of the synthesis procedure, the magnetic composites were successfully obtained. The Fe3O4 is nanometric (about 10 nm) and the weight percentage is sample-dependent. It decorates the HNT’s surface and also forms aggregates linking the nanotubes in Fe3O4-rich samples. Thermodynamic and kinetic experiments showed different adsorption capacities of OFL, ranging from 23 to 45 mg g−1. The kinetic process occurred within a few minutes, independently of the composite. The capability of the three HNT/Fe3O4 in removing the OFL was confirmed under realistic conditions, when OFL was added to tap, river, and effluent waters at µg L−1 concentration. No acute toxicity of the composites was observed on freshwater organisms. Despite the good results obtained for all the composites, the sample by co-precipitation is the most performant as it: (i) is easily magnetically separated from the media after the use; (ii) does not undergo any degradation after three adsorption cycles; (iii) is synthetized through a low-cost procedure. These features make this material an excellent candidate for removal of OFL from water.
- 6 December 2022
- Published by MDPI AG in Nanomaterials
- Vol. 12 (23) , 4330
Open AccessFe3O4-Halloysite Nanotube Composites as Sustainable Adsorbents: Efficiency in Ofloxacin Removal from Polluted Waters and Ecotoxicity
The present work aimed at decorating halloysite nanotubes (HNT) with magnetic Fe3O4 nanoparticles through different synthetic routes (co-precipitation, hydrothermal, and sol-gel) to test the efficiency of three magnetic composites (HNT/Fe3O4) to remove the antibiotic ofloxacin (OFL) from waters. The chemical–physical features of the obtained materials were characterized through the application of diverse techniques (XRPD, FT-IR spectroscopy, SEM, EDS, and TEM microscopy, thermogravimetric analysis, and magnetization measurements), while ecotoxicity was assessed through a standard test on the freshwater organism Daphnia magna. Independently of the synthesis procedure, the magnetic composites were successfully obtained. The Fe3O4 is nanometric (about 10 nm) and the weight percentage is sample-dependent. It decorates the HNT’s surface and also forms aggregates linking the nanotubes in Fe3O4-rich samples. Thermodynamic and kinetic experiments showed different adsorption capacities of OFL, ranging from 23 to 45 mg g−1. The kinetic process occurred within a few minutes, independently of the composite. The capability of the three HNT/Fe3O4 in removing the OFL was confirmed under realistic conditions, when OFL was added to tap, river, and effluent waters at µg L−1 concentration. No acute toxicity of the composites was observed on freshwater organisms. Despite the good results obtained for all the composites, the sample by co-precipitation is the most performant as it: (i) is easily magnetically separated from the media after the use; (ii) does not undergo any degradation after three adsorption cycles; (iii) is synthetized through a low-cost procedure. These features make this material an excellent candidate for removal of OFL from water.